<DOC>
	<DOCNO>NCT02612155</DOCNO>
	<brief_summary>This study test safety efficacy infusion baby 's ( autologous ) umbilical cord blood compare placebo baby bear history sign hypoxic-ischemic brain injury .</brief_summary>
	<brief_title>A Multi-site Study Autologous Cord Blood Cells Hypoxic Ischemic Encephalopathy</brief_title>
	<detailed_description>The purpose phase II study ass safety efficacy two intravenous infusion autologous volume red blood cell reduce nucleated umbilical cord blood cell compare placebo neonate neonatal encephalopathy undergo hypothermia treatment . Efficacy estimate one year survival score Bayley III score three domain equal great 85 . This randomized , double-blind , placebo control multi-site trial 160 infant qualify cooling .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Hypoxia-Ischemia , Brain</mesh_term>
	<criteria>1 . NICHD Neonatal Research Network Hypothermia Trial inclusion criterion 2 . Mothers must consent give verbal assent cord blood collection delivery , cord blood must available volume red blood cell reduction 45 hour age 3 . The infant must able receive least one dose autologous cord blood 48 hour age 4 . All infant must sign encephalopathy within 6 hour age 1 . Major congenital chromosomal abnormality 2 . Severe growth restriction ( birth weight &lt; 1800 g ) 3 . Opinion attend neonatologist study may interfere treatment safety subject 4 . Moribund neonates treatment plan 5 . Infants born mother know HIV , Hepatitis B , Hepatitis C active syphilis CMV infection pregnancy 6 . Infants suspect overwhelming sepsis 7 . ECMO initiate likely first 48 hour life</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Hours</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hypoxic-ischemic encephalopathy</keyword>
	<keyword>autologous cord blood cell</keyword>
	<keyword>newborn infant</keyword>
</DOC>